Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fostamatinib in RA (OSKIRA-1)
NCT01197521Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Sep 2010
- Primary completion
- Nov 2012
- Modality
- Small Molecules
- Countries
- 17
01
Overview
Phase 3, randomised, double-blind trial of fostamatinib in rheumatoid arthritis (RA) (3 arms), sponsored by AstraZeneca. Primary endpoints: American College of Rheumatology 20% Response at 24 weeks and Modified Total Sharp Score at 24 weeks. Started Sep 2010; status: completed.
02
Drugs
fostamatinib
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT01197521.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01197521.